125 Influence of pulmonary exacerbations on health status of cystic fibrosis patients. Health UTIlities and Quality of Life Study (HUTIQOL)

Girón, Rosa; Reig, J.P.; Olveira, Casilda; Pastor, María Dolores; Prados, Concepción; Quintana‐Gallego, Esther; Pérez‐Ruiz, Elisabeth; Solé, A.; Máiz, Luís

doi:10.1016/s1569-1993(16)30363-0

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review only considered full-text articles. Abstracts identified in this review included a study by Choyce et al [53] that evaluated the impact of home monitoring in reducing hospital admission and HSU through the EQ-5D-5L; Giron et al [54] evaluated EQ-5D-3L-derived HSUs in Spanish patients who had mild or moderate PEx events; L'abbe et al [55] evaluated HSUs in CF lung transplantation patients; and Yarlas et al [56] evaluated HSUs in CF patients in Europe and the US. These studies would prove useful additions to this review if/when a future update is available to expand on these abstracts.…”

Section: Limitations Of This Reviewmentioning

confidence: 99%

Health State Utility Data in Cystic Fibrosis: A Systematic Review

Mohindru

Turner

Sach

et al. 2019

PharmacoEconomics Open

View full text Add to dashboard Cite

Introduction Cystic fibrosis (CF) is a life-limiting, hereditable condition, with the highest prevalence in Europe. CF treatments have led to improvements in clinical symptoms, disease management and decelerated disease progression. However, little is known about the health state utility (HSU) associated with CF disease states, adverse events, and changes in disease severity. Although HSU data have contributed to existing health economic modelling studies, a lack of such data have been highlighted. This systematic review aims to provide a summary of HSU-related research in CF and highlight related research gaps. Methods Online searches were performed in six databases and studies in any of the following categories were included: (1) estimation of HSUs in CF; (2) mapping studies between patient-reported outcome measures (PROMs) and HSUs; (3) economic evaluations on the management of CF that report primary HSU data; and (4) any CF clinical trial that reported HSU as an outcome. Results A total of 17 studies were reviewed, of which 12 provided HSU values for specific CF populations. The remaining five articles provided HSU data that were broken down by CF relevant health states, including lung transplantations, pulmonary exacerbation (PEx) events and forced expiratory volume in 1 s (FEV 1). Conclusion Current HSU data in CF are limited and there is considerable scope for further research, both in providing HSU values for CF and in investigating methods for HSU elicitation/evaluation in CF populations.

show abstract